Meeting
2013 ASCO Annual Meeting
A phase Ib study of gemcitabine plus PEGPH20 (pegylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer.
Authors
Sunil R. Hingorani
Fred Hutchinson Cancer Research Center, Seattle, WA
Sunil R. Hingorani , William Proctor Harris , J. Thaddeus Beck , Boris A. Berdov , Stephanie Ann Wagner , Eduard M. Pshevlotsky , Sergei Tjulandin , Oleg Gladkov , Randall F. Holcombe , Ping Jiang , Daniel C. Maneval , Joy Zhu , Craig E. Devoe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT01453153
Citation
J Clin Oncol 31, 2013 (suppl; abstr 4010)
DOI
10.1200/jco.2013.31.15_suppl.4010
Abstract #
4010
Poster Bd #
2
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Final results of a phase Ib study of gemcitabine plus PEGPH20 in patients with stage IV previously untreated pancreatic cancer.
First Author: Sunil R. Hingorani
Poster
2015 Gastrointestinal Cancers Symposium
Exploratory biomarker results from early investigation of PEGPH20 in combination with gemcitabine (Gem) in patients with pancreatic cancer (PDA).
First Author: Sunil R. Hingorani
Poster
2017 Gastrointestinal Cancers Symposium
A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients (pts) with stage IV pancreatic cancer.
First Author: Gayle S. Jameson
Poster
2014 Gastrointestinal Cancers Symposium
Second-line gemcitabine plus nab-paclitaxel (G+A) for advanced pancreatic cancer (APC) after first-line FOLFIRINOX: Single institution retrospective review of efficacy and toxicity.
First Author: Yue Zhang